Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model

Neoplasia

Volumn 11, Issue 2, 2009, Pages 177-186

  Halin, Sofia ^a   Rudolfsson, Stina Häggstr̈m ^a   Van Rooijen, Nico ^b   Bergh, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 1BETA; LIPOSOME; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; COPENHAGEN RAT; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE FUNCTION; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; TUMOR GROWTH; TUMOR VOLUME; UNINDEXED SEQUENCE; UPREGULATION;

EID: 61349113394     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81338     Document Type: Article

References (34)

1. Bingle L, Brown NJ, and Lewis CE (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196, 254-265.
2. Balkwill F and Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet 357, 539-545.
3. Condeelis J and Pollard JW (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266.
4. Coussens L Mand Werb Z (2002). Inflammation and cancer. Nature 420, 860-867.
5. Pollard JW (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4, 71-78.
6. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, and Bergh A (2000). Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 17, 445-451.
7. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, and Thompson TC (2000). Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 60, 5857-5861.
8. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, and Pienta KJ (2007). CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 9, 556-562.
9. Halin S, Hammarsten P, Wikstrom P, and Bergh A (2007). Androgen-insensitive prostate cancer cells transiently respond to castration treatment when growing in an androgen-dependent prostate environment. Prostate 67, 370-377.
10. Hammarsten P, Halin S, Wikstom P, Henriksson R, Rudolfsson SH, and Bergh A (2006). Inhibitory effects of castration in an orthotopic model of androgenindependent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res 12, 7431-7436.
11. Van Rooijen N and Sanders A (1994). Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174, 83-93.
12. Isaacs JT, Isaacs WB, Feitz WF, and Scheres J (1986). Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9, 261-281.
13. Franck-Lissbrant I, Haggstrom S, Damber JE, and Bergh A (1998). Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139, 451-456.
14. Johansson A, Rudolfsson SH, Wikstrom P, and Bergh A (2005). Altered levels of angiopoietin 1 and tie 2 are associated with androgen-regulated vascular regression and growth in the ventral prostate in adult mice and rats. Endocrinology 146, 3463-3470.
15. Lissbrant IF, Hammarsten P, Lissbrant E, Ferrara N, Rudolfsson SH, and Bergh A (2004). Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1-3)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 58, 57-65.
16. Van Rooijen N and Sanders A (1996). Kupffer cell depletion by liposomedelivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid. Hepatology 23, 1239-1243.
17. Yu JL and Rak JW (2003). Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 5, 83-88.
18. Murdoch C, Giannoudis A, and Lewis CE (2004). Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234.
19. Biswas SK, Sica A, and Lewis CE (2008). Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180, 2011-2017.
20. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, and Wiegand SJ (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998.
21. Bergmann CE, Hoefer IE, Meder B, Roth H, van Royen N, Breit SM, Jost MM, Aharinejad S, Hartmann S, and Buschmann IR (2006). Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J Leukoc Biol 80, 59-65.
22. Hirose N, Maeda H, Yamamoto M, Hayashi Y, Lee GH, Chen L, Radhakrishnan G, Rao P, and Sasaguri S (2008). The local injection of peritoneal macrophages induces neovascularization in rat ischemic hind limb muscles. Cell Transplant 17, 211-222.
23. Joseph IB and Isaacs JT (1998). Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 90, 1648-1653.
24. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, and Wainstok R (2007). Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 127, 2031-2041.
25. Miselis NR, Wu ZJ, Van Rooijen N, and Kane AB (2008). Targeting tumorassociated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7, 788-799.
26. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, and Schwendener RA (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95, 272-281.
27. Galarneau H, Villeneuve J, Gowing G, Julien JP, and Vallieres L (2007). Increased glioma growth in mice depleted of macrophages. Cancer Res 67, 8874-8881.
28. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, and Leenen PJ (2004). Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 172, 4410-4417.
29. Lissbrant IF, Lissbrant E, Damber JE, and Bergh A (2001). Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35, 437-452.
30. Sakamoto S, Ryan AJ, and KyprianouN(2008). Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem 103, 691-708.
31. Egeblad M and Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174.
32. Coussens LM, Tinkle CL, Hanahan D, and Werb Z (2000). MMP-9 supplied by bonemarrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490.
33. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol PF, Glass CK, Rosenfeld MG, et al. (2006). Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124, 615-629.
34. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, and Apte RN (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100, 2645-2650.